Author's response to reviews

Title: Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: Implications for clinical evaluation

Authors:

Jessica E Bohonowych (bohonowy@musc.edu)
Shuping Peng (shuping@csu.edu.cn)
Udhayakumar Gopal (gopal@musc.edu)
Michael W Hance (hance@musc.edu)
Shane B Wing (shanewing@gmail.com)
Kelley M Argraves (argravek@musc.edu)
Karen Lundgren (karenlundgren@biogenidec.com)
Jennifer S Isaacs (isaacsj@musc.edu)

Version: 3 Date: 15 November 2011

Author's response to reviews: see over
Dear Editor,

We appreciate the useful comments on our manuscript ‘Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: Implications for clinical evaluation.’ We have adequately addressed all scientific concerns. However, Reviewer #1 indicated that ‘some description or representative literature on EC154 as a novel Hsp90 inhibitor is highly recommended.’ In response, we have the following information, as mentioned here and added to the manuscript.

EC154 is a compound with improved properties (potency, pharmacokinetic and pharmacodynamic) over BIIB021, the first oral synthetic Hsp90 inhibitor to reach clinical trials (Lundgren et al. 2009 Mol Cancer Therapeutics). EC154 binds to the Hsp90 ATP binding site in a manner similar to EC144 (Yun et al. 2011 J Immunology).

Unfortunately, due to the proprietary nature of this compound, we do not have further information about the specific structure. We hope that this will be sufficient information in regards to this compound.

Best regards,

Jennifer Isaacs, Ph.D.